| Dr Lisa Anne Catapano, MD | |
|
1555 Connecticut Ave Nw Ste 300w, Washington, DC 20036-1125 | |
| (202) 516-6622 | |
| (301) 709-9771 |
| Full Name | Dr Lisa Anne Catapano |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1555 Connecticut Ave Nw Ste 300w, Washington, District Of Columbia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184872301 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD035181 (District Of Columbia) | Primary |
| Entity Name | Medical Faculty Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417990581 PECOS PAC ID: 4082528898 Enrollment ID: O20031117000341 |
News Archive
For patients with dialysis-related anemia, the risk of death is increased when hemoglobin levels remain persistently low over a period several months - not necessarily when they fluctuate over time, according to a study in the January Clinical Journal of the American Society of Nephrology.
Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Like countless other restaurateurs across California and the nation, Alex and Charity Prestifilippo have been caught in a precarious health-and-safety limbo.
Johns Hopkins researchers have figured out the specific job of a protein long implicated in tumors of the nervous system. Reporting on a new study described in the Sept. 12 issue of the journal Cell, they detail what they call the "matchmaking" activities of a fruit fly protein called Merlin, whose human counterpart, NF2, is a tumor suppressor protein known to cause neurofibromatosis type II when mutated.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lisa Anne Catapano, MD 1555 Connecticut Ave Nw Ste 300w, Washington, DC 20036-1125 Ph: (202) 516-6622 | Dr Lisa Anne Catapano, MD 1555 Connecticut Ave Nw Ste 300w, Washington, DC 20036-1125 Ph: (202) 516-6622 |
News Archive
For patients with dialysis-related anemia, the risk of death is increased when hemoglobin levels remain persistently low over a period several months - not necessarily when they fluctuate over time, according to a study in the January Clinical Journal of the American Society of Nephrology.
Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Like countless other restaurateurs across California and the nation, Alex and Charity Prestifilippo have been caught in a precarious health-and-safety limbo.
Johns Hopkins researchers have figured out the specific job of a protein long implicated in tumors of the nervous system. Reporting on a new study described in the Sept. 12 issue of the journal Cell, they detail what they call the "matchmaking" activities of a fruit fly protein called Merlin, whose human counterpart, NF2, is a tumor suppressor protein known to cause neurofibromatosis type II when mutated.
› Verified 6 days ago
Mr. Joel Edward Kleinman, M.D., PH.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3734 Jenifer St Nw, Washington, DC 20015 Phone: 202-363-4846 Fax: 202-363-2025 | |
Dr. John Shill, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2220 20th St Nw, Ste 71, Washington, DC 20009 Phone: 202-320-4417 | |
Nubia Amparo Chong, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 I St Nw Ste 400e, Washington, DC 20005 Phone: 202-902-7324 Fax: 848-213-0063 | |
Dr. Jerrold Thomas O'rourke Jr., M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1330 New Hampshire Ave Nw, Ste 113, Washington, DC 20036 Phone: 202-463-6634 Fax: 202-463-6638 | |
Dr. Jaime Suarez, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2401 E Street Nw - M/med/qi - Sa-1, Department Of State, Washington, DC 20522 Phone: 202-663-2453 Fax: 202-663-3247 | |
Dr. Estela M. Gonzalez, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2333 Ontario Rd Nw, Washington, DC 20009 Phone: 202-420-7121 | |
Dr. Richard Martin Restak, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1800 R St Nw, Suite C-3, Washington, DC 20009 Phone: 202-462-0455 Fax: 202-462-0340 |